Follow-up Study of Individuals with Autoantibodies Against Ro/SSA and La/SSB

NCT ID: NCT06594861

Last Updated: 2024-09-19

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 500 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2024-02-09
• Study Completion Date: 2038-12-31

Brief Summary

In this study, individuals with autoantibodies against Ro/SSA and La/SSB will be followed with regard to clinical manifestations and immunological parameters to identify immunological changes, environmental factors, and early clinical symptoms that characterize the progression from serological autoreactivity to clinically manifest disease.

Detailed Description

Autoimmune diseases are a diverse group of conditions characterized by chronic inflammation and tissue damage. In systemic autoimmune diseases such as Sjögren disease and systemic lupus erythematosus (SLE), two specific types of autoantibodies targeting the bodys own proteins, Ro/SSA and La/SSB, are often present.

It is well known that some individuals with autoantibodies against Ro/SSA and/or La/SSB never develop any systemic rheumatic disease, while in others, the presence of these autoantibodies is a sign of impending disease. The condition of so-called serological autoreactivity, which can persist for decades, and how clinical disease subsequently develops is very little studied. There is currently a lack of knowledge regarding the environmental factors that contribute to the emergence of autoantibodies against Ro/SSA and/or La/SSB and the immunological mechanisms that lead to disease development in some individuals but not in others.

This project aims to enhance the understanding of the condition of serological autoreactivity against Ro/SSA and La/SSB. The specific goal is to identify immunological changes, environmental factors, and early clinical symptoms that characterize the progression from serological autoreactivity to clinically apparent disease. Understanding the immunological mechanisms that trigger the transition to disease is crucial for enabling earlier diagnosis and treatment, as well as for better comprehending the fundamental mechanisms underlying the development of autoimmune disease.

This will be achieved by:

1. Clinically characterizing at-risk individuals who carry autoantibodies against Ro/SSA and/or La/SSB through medical consultations at a rheumatology specialist clinic.

2. Immunologically characterizing at-risk individuals in comparison with healthy individuals through blood sampling and immunological analyses.

3. Collecting data on exposure to environmental and lifestyle factors that could potentially increase the risk of autoimmunity.

Study participants are offered annual follow-up assessments for four years after the inclusion visit (i.e., a total of 4 study visits per participant). Participants that develop new symptoms during the study are be offered additional medical visits for assessment. At the final follow-up visit, participants will be asked for their consent to be contacted by phone to inquire about any new symptoms and to schedule new blood tests after two and five years, respectively.

Conditions

Autoantibodies

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

Individuals with autoantibodies against Ro/SSA and/or La/SSB

No intervention

Intervention Type: OTHER

No intervention.

Individuals without autoantibodies against Ro/SSA and/or La/SSB

No intervention

Intervention Type: OTHER

No intervention.

Interventions

No intervention

No intervention.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

To be included in the risk group, the following criteria must be met:

• At least one instance of testing positive for Ro/SSA or La/SSB, regardless of the method used.

To be included in the control group, the individual must:

• Have no rheumatologic disease and no autoantibodies against Ro/SSA or La/SSB.

Exclusion Criteria

1. Below 18 years of age

2. Inability to consent to their own participation

3. Ongoing infection or severe illness where the study physician deems participation in the study not to be in the individuals best interest

4. Inability to read and understand Swedish, and therefore unable to complete the forms and questionnaires included in the project

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Karolinska Institutet

OTHER

Sponsor Role: lead

Responsible Party

Albin Björk

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Centrum för reumatologi

Stockholm, , Sweden

Site Status: RECRUITING

Countries

Sweden

Central Contacts

Albin Björk, MD, PhD

Role: CONTACT

albin.bjork@ki.se

+46 8-123 687 04

Facility Contacts

Albin Björk, MD, PhD

Role: primary

albin.bjork@ki.se

+46 8-123 687 04

Other Identifiers

2023-04569-01

Identifier Type: -

Identifier Source: org_study_id